Some nations could be paying ten times the price of Paxlovid’s generic equivalent, as WHO chief calls for treatment access to battle acute and long COVID-19
Rich countries have secured almost three times as many courses of a World Health Organisation (WHO)-recommended COVID-19 medicine, Pfizer’s Paxlovid, according to new analysis from Oxfam and the People’s Vaccine Alliance.
The continent of 1.3 billion people saw a 37% rise in new cases over the past week, Ahmed Ogwell, acting director of the Africa Centers for Disease Control and Prevention, said Thursday.
Recent Comments